Matthias Will, M.D. Joins Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company known for its development of next-generation programmed T cell therapies, has announced a significant addition to its executive team. Matthias Will, M.D., has been appointed as the Chief Development Officer. With his extensive background in the biotech industry, Dr. Will is well-suited to lead the company’s development strategies and initiatives.
Dr. Will's Experience
Dr. Will brings years of expertise in pharmaceutical product development to Autolus. He has successfully achieved key regulatory approvals for various cancer treatments throughout his career. Dr. Christian Itin, the Chief Executive Officer at Autolus, commended Dr. Will's impressive track record, stating that his leadership will greatly aid the company in expanding its innovative treatment options.
Leadership in Oncology Development
Upon his appointment, Dr. Will shared his enthusiasm for the exciting opportunities that await Autolus as it prepares to commercialize its first product, obe-cel. This innovative therapy targets relapsed or refractory adult B-cell acute lymphoblastic leukemia (B-ALL). Eager about his new role, Dr. Will looks forward to working with the talented team at Autolus to bring impactful treatments to patients, leveraging their scientific breakthroughs.
Dr. Will's Career Prior to Autolus
Before joining Autolus, Dr. Will was the Chief Medical Officer at Dren Bio, Inc. There, he successfully led the clinical team focused on hematologic cancers. His previous positions at CRISPR Therapeutics and CytomX Therapeutics provided him with invaluable insights into clinical development and regulatory strategies. Additionally, Dr. Will has advised on projects with McKinsey & Company, further enriching his diverse experience.
Educational Background
Dr. Will earned his medical degree from Hannover Medical School. He enhanced his expertise in hematology and oncology at the University of Tübingen in Germany. This strong academic foundation complements his practical experiences, enabling him to effectively contribute to Autolus' mission.
About Autolus Therapeutics
Autolus specializes in advancing T cell therapies aimed at treating various cancers and autoimmune disorders. Utilizing proprietary technologies, the company strives to develop therapies that are precisely designed to target and eliminate specific cells. Their dedication has resulted in a robust pipeline that includes innovative treatments for both hematological malignancies and solid tumors.
Understanding the Significance of obe-cel
Among the therapies currently in development is obe-cel (AUTO1), a promising option for patients with adult B-ALL. What sets obe-cel apart from traditional CAR T cell therapies is its rapid target-binding mechanism, which enhances patient safety and decreases toxicity. Clinical trials have returned promising results, particularly among patients experiencing durable remissions. Anticipated results from upcoming pivotal trials are expected to drive significant progress in the treatment of B-ALL.
Insights from Clinical Trials
Autolus has been running extensive Phase 1b/2 clinical trials for obe-cel, involving many patients at leading institutions. These trials assess not only overall response rates but also focus on monitoring remission and safety, generating essential data that could shape the future landscape of cancer treatments.
Contact Information for Autolus
For more information, Autolus provides dedicated contact points. You can reach Olivia Manser at +44 (0) 7780 471 568 or via email at o.manser@autolus.com. Julia Wilson is also available at +44 (0) 7818 430877 or j.wilson@autolus.com. For inquiries through S.A. Noonan Communications, contact Susan A. Noonan at +1-917-513-5303 or via email at susan@sanoonan.com.
Frequently Asked Questions
Who is Matthias Will, M.D.?
Matthias Will, M.D. is the newly appointed Chief Development Officer at Autolus Therapeutics and has extensive experience in the pharmaceutical sector.
What does Autolus Therapeutics specialize in?
Autolus Therapeutics specializes in developing advanced programmed T cell therapies aimed at treating cancer and autoimmune diseases.
What is obe-cel?
Obe-cel is an investigational chimeric antigen receptor (CAR) T cell therapy designed specifically for adult patients suffering from relapsed or refractory B-ALL.
What makes obe-cel different from other therapies?
Obe-cel stands out due to its unique rapid target-binding mechanism, which enhances safety and reduces toxicity, outperforming conventional CAR T cell therapies.
How can I contact Autolus for more information?
You can reach out to Autolus by contacting Olivia Manser at +44 (0) 7780 471 568 or emailing o.manser@autolus.com for any inquiries.
